# Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

> **NCT02657356** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 202 (actual)

## Conditions studied

- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Placebo capsules
- **DRUG:** Bardoxolone methyl capsules

## Key facts

- **NCT ID:** NCT02657356
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-04
- **Primary completion:** 2020-05-07
- **Final completion:** 2020-05-07
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** Exposure of these high-risk patients to clinic or in-person visits during the pandemic presented an unacceptable risk to their health
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657356, "Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02657356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*